Trials / Completed
CompletedNCT00408434
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
A Phase I Dose Finding Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Patients With Advanced or Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-7017 | CS-7017 0.05mg and 1.0mg tablets |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2006-12-07
- Last updated
- 2020-10-19
- Results posted
- 2020-10-19
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00408434. Inclusion in this directory is not an endorsement.